Table 1 Characteristics at diagnosis for... | American Society of Hematology

Table 1

Characteristics at diagnosis for patients with available iFISH cytogenetics (n = 123)

Characteristic	No.*	%	Median	Range
Clinical parameters
Age, y			55	37-70
Sex
Male	69	56
Female	54	44
Karnofsky index (%)			90	70-100
Hematologic parameters
AL only/AL + MM I†	107/16	87/13
AL only/AL + MM I‡	53/70	43/57
Bone marrow plasmocytosis (%)			10	1-48
Intact immunoglobulin
Yes	53	43
No	70	57
Light chain restriction
κ	23	19
λ	100	81
dFLC, mg/L			143.4	0-3194
κ			245.0	0-2679
λ			139.1	1.7-3194
dFLC (≥180 mg/L cutoff)	51/118	43
κ	12/22	55
λ	39/96	41
Organ involvement
No. of involved organs			2	1-5
Heart involvement	70	57
NYHA stage§
0	14
I	30
II	18
III	7
Mayo stage\|\|
I	48
II	54
III	16
ND	5
NT-proBNP, ng/L			441	19-27 405
Heart transplantation before ABSCT	10	8
Revised Mayo stage¶
I	51
II	41
III	16
IV	7
ND	8
Renal involvement	82	67
MDRD, mL/min#			80	5-262
Albumin, g/L#			33	18-46
Proteinuria, g/d#			7.4	0.2-20.8
Soft tissue involvement	44	36
GI tract involvement	35	28
Liver involvement	21	17
Neuropathy	20	16
Time period
2003-2006	33
2007-2010	51
2011-2014	39
Therapy
Induction
None	53
Dexamethasone based	38
Bortezomib based	32
Mobilization
CAD	85
Cyclophosphamide	16
G-CSF alone	21
HDM
Full dose	83
Adjusted to MDRD	33
Effectively reduced	7

Characteristic	No.*	%	Median	Range
Clinical parameters
Age, y			55	37-70
Sex
Male	69	56
Female	54	44
Karnofsky index (%)			90	70-100
Hematologic parameters
AL only/AL + MM I†	107/16	87/13
AL only/AL + MM I‡	53/70	43/57
Bone marrow plasmocytosis (%)			10	1-48
Intact immunoglobulin
Yes	53	43
No	70	57
Light chain restriction
κ	23	19
λ	100	81
dFLC, mg/L			143.4	0-3194
κ			245.0	0-2679
λ			139.1	1.7-3194
dFLC (≥180 mg/L cutoff)	51/118	43
κ	12/22	55
λ	39/96	41
Organ involvement
No. of involved organs			2	1-5
Heart involvement	70	57
NYHA stage§
0	14
I	30
II	18
III	7
Mayo stage\|\|
I	48
II	54
III	16
ND	5
NT-proBNP, ng/L			441	19-27 405
Heart transplantation before ABSCT	10	8
Revised Mayo stage¶
I	51
II	41
III	16
IV	7
ND	8
Renal involvement	82	67
MDRD, mL/min#			80	5-262
Albumin, g/L#			33	18-46
Proteinuria, g/d#			7.4	0.2-20.8
Soft tissue involvement	44	36
GI tract involvement	35	28
Liver involvement	21	17
Neuropathy	20	16
Time period
2003-2006	33
2007-2010	51
2011-2014	39
Therapy
Induction
None	53
Dexamethasone based	38
Bortezomib based	32
Mobilization
CAD	85
Cyclophosphamide	16
G-CSF alone	21
HDM
Full dose	83
Adjusted to MDRD	33
Effectively reduced	7

ABSCT, autologous blood stem cell transplantation; CAD, cyclophosphamide-doxorubicin-dexamethasone; G-CSF, granulocyte colony-stimulating factor; MDRD, modification of diet in renal disease; ND, not determined; NT-proBNP, N-terminal prohormone brain natriuretic peptide; NYHA, New York Heart Association.

Frequencies (no./N) of the parameters (except AL only/AL + MM I [no./no.]). If no denominator is shown, N = 123.

†

Applying the bone marrow plasmocytosis cutoff of 30% to distinguish between AL only and AL + MM I, according to Skinner et al.²

‡

Applying the cutoff of 10% for bone marrow plasmocytosis according to Kourelis et al.³⁴

Only patients with heart involvement are shown. One patient could not be evaluated for NYHA stage because of disabling muscle involvement. All NYHA stage III patients were among the patients who received heart transplantation before HDM.

Defined according to Dispenzieri et al.³⁰

Defined according to Kumar et al.³¹

Only patients with renal involvement are shown.

View Large

This Feature Is Available To Subscribers Only